(FGEN) - Earnings & Price History

FGEN: - 54.975, $4.04B, -0.88 (-1.57%)

Sector: Healthcare - Industry: Biotechnology

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.Key Statistics

Past FGEN reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-01AMC-0.5325.225.6525.5524.327.3-0.39%-1.37%-1.75%1.04M
2016-11-08AMC-0.62015.917.517.22010.06%▲14.29%25.79%3.23M
2016-08-08AMC0.3619.1919.4719.4618.7619.64-0.05%-1.39%-1.44%627.22K
2016-05-09AMC-0.5617.9416.73171718.271.61%5.53%7.23%834.23K
2016-02-29AMC-0.411817.3317.5715.7818.021.38%2.45%3.87%836.83K
2015-11-12AMC-0.5926.225.2924.924.9626.3-1.54%▲5.22%3.60%642.31K
2015-08-13AMC0.7325.922.1822.282225.940.45%16.25%16.77%1.55M
2015-05-12-0.5223.623.8123.524.17-0.88%539.91K
2015-03-26AMC-0.929.8529.5129.5129.230.741.15%1.15%140.76K

Login | Register
Saturday Nov 17, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades